Form 4: Aclaris Therapeutics Director Christopher Molineaux Reports New Equity Grants and RSU Vesting

Aclaris Therapeutics, Inc. Director Christopher P. Molineaux reported the acquisition of 4,793 common shares through RSU vesting and new grants of 42,350 stock options and 11,580 restricted stock units.

Summary

• Director Christopher P. Molineaux acquired 4,793 shares of Aclaris Therapeutics, Inc. common stock on June 6, 2025, through the vesting of restricted stock units.
• Following this transaction, Mr. Molineaux directly holds 57,956 shares of common stock.
• On June 5, 2025, Mr. Molineaux was granted 42,350 stock options with an exercise price of $1.56 per share, which will vest in twelve equal monthly installments starting July 5, 2025, and expire on June 4, 2035.
• Also on June 5, 2025, Mr. Molineaux was granted 11,580 restricted stock units, which will vest in a single installment on June 5, 2026.
• All grants were made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.

Sentiment

Score: 7

Explanation: The sentiment is positive as it reflects routine equity compensation for a director, aligning their interests with shareholders through new grants and increased direct ownership. There are no reported sales or negative transactions.

Positives

• Director Christopher P. Molineaux received new equity grants, including 42,350 stock options and 11,580 restricted stock units, indicating continued alignment of interests with shareholders.
• The vesting of 4,793 restricted stock units into common stock increases the director's direct ownership in the company.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, suggesting pre-planned and routine compensation.

Future Outlook

NA

Industry Context

NA

Corporate Governance

Related Party Transactions

• The reported transactions involve equity grants and vesting to a director of Aclaris Therapeutics, Inc., which are considered related-party transactions as they involve an insider of the company.

Stakeholder Impact

• Shareholders: The grants align the director's interests with shareholders by increasing their equity stake and providing incentives tied to future company performance.
• Employees: No direct impact on employees mentioned.
• Customers: No direct impact on customers mentioned.
• Suppliers: No direct impact on suppliers mentioned.
• Creditors: No direct impact on creditors mentioned.

Next Steps

• Monthly vesting of 42,350 stock options commencing July 5, 2025.
• Vesting of 11,580 restricted stock units on June 5, 2026.

Key Dates

Keywords

Aclaris Therapeutics, ACRS, Form 4, Insider Transaction, Stock Option, Restricted Stock Units, Equity Grant, Director Compensation, Beneficial Ownership, Christopher Molineaux